What it's for (Indications)
- Menotropin, a preparation containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity derived from the urine of postmenopausal women, is clinically indicated for several crucial applications in reproductive medicine.
- Primarily, it is used for the development of multiple ovarian follicles in ovulatory patients undergoing Assisted Reproductive Technologies (ART), such as in vitro fertilization (IVF), gamete intrafallopian transfer (GIFT), and zygote intrafallopian transfer (ZIFT).
- This application aims to optimize the number of retrieved oocytes to enhance the success rates of these complex procedures.
- Additionally, menotropin is indicated for the induction of ovulation and pregnancy in anovulatory infertile women (classified as Group II, including those with polycystic ovarian syndrome) who have not responded adequately to prior clomiphene citrate therapy.
- Its use in these patients is contingent upon the cause of infertility being functional rather than primary ovarian failure, ensuring a responsive ovarian reserve.
- The primary goal is to stimulate follicular growth leading to a successful ovulatory event.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of menotropin is highly individualized and requires meticulous titration under the direct supervision of a physician specializing in infertility treatment, due to the significant inter-patient variability in ovarian response. For the induction of ovulation in anovulatory women, an initial subcutaneous or intramuscular dose of 75 International Units (IU) of FSH and 75 IU of LH activity is typically administered daily for 7 to 12 days. Subsequent dose adjustments, generally not exceeding 150 IU per day, are made based on daily or every-other-day monitoring of ovarian follicular development via transvaginal ultrasonography and serum estradiol levels. Once adequate follicular maturation is achieved, a single dose of human chorionic gonadotropin (hCG) is administered to trigger ovulation. In Assisted Reproductive Technologies (ART), initial daily doses may range from 150 IU to 225 IU, starting on cycle day 2 or 3, with adjustments made based on ovarian response. The maximum daily dose generally should not exceed 450 IU, and treatment duration typically ranges from 7 to 20 days. Careful dosing is paramount to minimize risks such as Ovarian Hyperstimulation Syndrome (OHSS) and multiple gestations. |
Safety & Warnings
Common Side Effects
- Treatment with menotropin can be associated with a range of side effects, from common and mild to rare and severe.
- The most frequently reported adverse reactions include localized injection site pain, redness, swelling, or bruising.
- Systemic common effects often encompass headache, mild abdominal discomfort, breast tenderness, and nausea.
- A significant and potentially severe complication is Ovarian Hyperstimulation Syndrome (OHSS), which can manifest as ovarian enlargement, abdominal distension, ascites, dyspnea, pleural effusion, and electrolyte imbalances; severe cases can be life-threatening and involve renal failure or thromboembolic events.
- The risk of multiple gestations, including high-order multiples, is substantially increased.
- Other less common but serious adverse events include ectopic pregnancy, ovarian torsion, arterial thromboembolism (e.
- g.
- , pulmonary embolism, stroke), and hypersensitivity reactions, including anaphylaxis.
- Patients must be educated to report any signs of severe abdominal pain, sudden weight gain, or shortness of breath immediately to their healthcare provider.
Serious Warnings
- Black Box Warning: Menotropin, while a vital therapeutic agent in reproductive medicine, does not typically carry a formal 'Black Box Warning' as designated by the U.S. Food and Drug Administration (FDA) in the same manner as certain other medications with extreme and unavoidable risks. However, the profound and potentially life-threatening risks associated with its administration necessitate an exceptionally strong and comprehensive 'Serious Warnings' advisory, which healthcare professionals and patients must address with the utmost diligence and caution. This emphasizes the critical nature of these risks, demanding rigorous management. **SERIOUS WARNINGS: OVARIAN HYPERSTIMULATION SYNDROME (OHSS) AND MULTIPLE GESTATIONS** Treatment with menotropin carries a significant and unavoidable risk of developing Ovarian Hyperstimulation Syndrome (OHSS), a severe medical complication that can progress rapidly and become life-threatening. Severe OHSS is characterized by acute ovarian enlargement, profound abdominal pain and distension, ascites, pleural effusion, oliguria, hemoconcentration, electrolyte disturbances, and a substantially increased risk of thromboembolic events (e.g., pulmonary embolism, stroke), and acute renal failure. Meticulous and continuous monitoring of ovarian response via transvaginal ultrasonography and serial serum estradiol measurements is absolutely paramount throughout the treatment cycle to identify and manage patients at high risk. Patients must receive comprehensive counseling regarding the early signs and symptoms of OHSS and be explicitly instructed to seek immediate medical attention should they experience severe abdominal discomfort, persistent nausea, vomiting, diarrhea, rapid weight gain, or difficulty breathing. Furthermore, menotropin therapy unequivocally increases the likelihood of multiple gestations, including high-order multiples. Multiple gestations inherently elevate obstetric risks for the mother (e.g., gestational diabetes, pre-eclampsia, preterm labor, hemorrhage) and perinatal risks for the neonates (e.g., prematurity, low birth weight, increased morbidity and mortality). Thorough and transparent discussion of these severe risks is mandatory with all patients prior to the initiation of menotropin treatment.
- Menotropin therapy necessitates rigorous clinical oversight by a healthcare professional experienced in fertility management and the complexities of gonadotropin treatment.
- The most critical warnings pertain to Ovarian Hyperstimulation Syndrome (OHSS) and multiple gestations.
- OHSS is a severe, potentially fatal complication, characterized by rapid ovarian enlargement, fluid accumulation in the abdominal and thoracic cavities, hemoconcentration, and increased risk of thromboembolic events.
- Close monitoring of ovarian response through serial transvaginal ultrasonography and serum estradiol measurements is imperative to identify patients at high risk and manage treatment appropriately.
- Patients must be thoroughly informed about the symptoms of OHSS and instructed to seek immediate medical attention if they experience severe abdominal pain, bloating, nausea, vomiting, sudden weight gain, or difficulty breathing.
- The risk of multiple gestations, particularly high-order multiples, is significantly elevated, carrying increased maternal and fetal risks including preterm birth, low birth weight, and obstetric complications.
- Other warnings include the potential for ovarian torsion, ectopic pregnancy, and thromboembolic events, even in the absence of severe OHSS.
How it Works (Mechanism of Action)
Menotropin, also identified as human menopausal gonadotropin (hMG), is a pharmacological agent comprising a balanced mixture of both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity. This therapeutic preparation is extracted and purified from the urine of postmenopausal women, who naturally excrete elevated levels of these gonadotropins due to the absence of ovarian feedback. The FSH component primarily acts on the granulosa cells within the ovarian follicles, stimulating their proliferation, differentiation, and subsequent production of estrogens (specifically estradiol) through the aromatization of androgens. Concurrently, the LH component plays a crucial synergistic role by stimulating the theca cells within the follicle to produce androgens, which serve as substrates for FSH-induced estrogen synthesis. LH is also vital for the final stages of follicular maturation, resumption of meiosis in the oocyte, and luteinization following ovulation. By mimicking the natural pulsatile release of endogenous pituitary gonadotropins, menotropin effectively promotes robust follicular growth, leading to ovulation in anovulatory women or facilitating the development of multiple follicles for assisted reproductive technologies, thereby overcoming endogenous gonadotropin deficiencies or optimizing reproductive outcomes.